Drug Trial Radar · NCT05776004
Blinded Efficacy and Safety Study of CAL02 IV Plus SOC in Subjects With Severe Community-Acquired Bacterial Pneumonia
Last checked: Nov 19, 2026Latest source record: Jan 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
276
Planned (sponsor's estimate)
Start
Jul 22, 2023
Primary completion
Feb 10, 2026
Study completion Sep 7, 2026
Sponsor
- Lead sponsor
- Eagle Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 20, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a placebo-controlled study to evaluate the addition of CAL02 to standard of care in treating hospitalized subjects diagnosed with severe community acquired bacterial pneumonia (SCABP) requiring critical care measures
Conditions
- Pneumonia, Bacterial
Interventions
CAL02Drug
CAL02 consists of a mixture of 2 liposomes and is a non-biological bacterial virulence neutralizer.
PlaceboDrug
Physiological 0.9% sodium chloride solution for iv administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy- clinical recoveryTime frame: 28 days
- Incidence of Treatment-Emergent Adverse EventsTime frame: 28 days
Locations
90 sites in 19 countries. Site status is shown where the registry gives one.
UCSF Hospital
Fresno, California
UF Health Shands Hospital
Gainesville, Florida
Northwestern Memorial Hospital
Chicago, Illinois
University of Nebraska Medical Center
Omaha, Nebraska
Wake Forest Baptist Health Hospital
Winston-Salem, North Carolina
Cleveland Clinic Fairview Hospital
Cleveland, Ohio
University of Texas Medical Branch
Galveston, Texas
Hospital Misericordia Nuevo Siglo
Córdoba, Argentina
Hospital Central
Mendoza, Argentina
Hospital Interzonal General de Agudo Dr Jose Pena
Bahía Blanca, Buenos Aires, Argentina
Hospital Italiano de Buenos Aires
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
Clinique Universitaire Saint Luc
Brussels, Belgium
Clinique Saint Pierre
Ottignies, Belgium
Chu-Ucl-Namur
Yvoir, Belgium
Unidade de Pesquisa Clinica da Faculdade de Medicina de Botucatu
Botucatu, Brazil
Hospital do Servidor Publico Estadual
São Paulo, Brazil
Hospital Mae de Deus
Porto Alegre, Rio Grande do Sul, Brazil
Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto
São José do Rio Preto, São Paulo, Brazil
Saint Paul's Hospital
Vancouver, Canada
Foothills Hospital Medical Centre
Calgary, Alberta, Canada
Peter Lougheed Centre
Calgary, Alberta, Canada
Rockyview General Hospital
Calgary, Alberta, Canada
South Health Campus Hospital
Calgary, Alberta, Canada
Pontificia Universidad Catolica de Chile
Santiago, Chile
Centro de Investigacion Clinica de la Costa SAS
Barranquilla, Colombia
Fundacion Cardioinfantil - Instituto de Cardiologia
Bogotá, Colombia
Krajska Zdravotni, a.s.
Teplice, Czechia
Krajska Zdravotni, a.s.
Ústí nad Labem, Czechia
Oblastní nemocnice Kolín, a.s., nemocnice Středočeského kraje
Zizkova, Czechia
CHU Angers
Angers, France
Centre Hospitalier Victor Dupouy
Argenteuil, France
Hopital Nord Franche Comte
Belfort, France
Hospital Fleyriat
Bourg-en-Bresse, France
Centre Hospitalier de Dieppe
Dieppe, France
Plateforme de Biologie Hospitalo-Universitaire
Dijon, France
Hopital Raymond Poincare
Garches, France
Pole Urgences Medecine Aigue CHU de Grenoble-Alpes
Grenoble, France
Hospital Dupuytren
Limoges, France
Centre Hospitalier de Melun-Senart
Melun, France
CHU de Nantes
Nantes, France
Showing 40 of 90 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.